Two Siblings of Hyperphenylalaninemia: Suggestion to a Genetic Variant of Phenylketonuria

Similar documents
Pathophysiology of the Phenylketonuria

Atypical Phenylketonuria

Research Article The Association between EEG Abnormality and Behavioral Disorder: Developmental Delay in Phenylketonuria

Amal Alamri. Phenylketonuria

New Developments 1n Screening for Inborn Errors of Metabolism*

PKU (Phenylketonuria) Serum HPLC Analysis Kit User Manual

Biochemical investigation of histidinaemia

Prerequisites Amino acid synthesis and degradation pathways. Integration of amino acid metabolic pathways with carbohydrate metabolic pathways.

University Journal of Pre and Paraclinical Specialities

An Improved Test for Phenylketonuria

Chapter 1: What is PKU?

JMSCR Volume 03 Issue 04 Page April 2015

AMERICAN ACADEMY OF PEDIATRICS. New Developments in Hyperphenylalaninemia. Committee on Nutrition

Most common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the. Inborn errors of metabolism (IEM)

Phenylalanine. in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency

PKU, a genetic disease, illustrating the principle:

Phenylketonuria and Its Variants

PKU (Phenylketonuria) Serum LC-MS/MS Analysis Kit User Manual

Metabolism of echitamine and plumbagin in rats

Amino Acid Oxidation and the Urea Cycle

retardation in infants. A wide variety of analytical methods for the analysis of

BAHAN AJAR IV Phenylketonurias (Phenylalanine Hydroxylase Deficiency) Nama Mata Kuliah/Bobot SKS : Sistem Neuropsikiatri / 8 SKS

Summary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism

Treatment of Classical Phenylketonuria

Amino acid Catabolism

ESPEN Congress Madrid 2018

HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up

INBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides

A. History Urinalysis is the oldest lab test still being performed today

INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU

Phenylketonuria Jonathan Baghdadi and Evan Marlin

HYPERGLYCINURIA: A FAMILY REPORT

A. We are constantly being tested (from birth). 1) Why? Test newborns to check for congenital health problems. 2) What does congenital mean?

Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age

IN DILUTE-LETHAL MICE

Committee Approval Date: August 15, 2014 Next Review Date: September 2015

Evaluation of Treatment Begun in First Three Months

A STUDY OF THE METABOLISM OF THEOBROMINE, THEOPHYLLINE, AND CAFFEINE IN MAN* Previous studies (1, 2) have shown that after the ingestion of caffeine

OF TRANSAMINASE IN RAT TISUES

Medical Foods for Inborn Errors of Metabolism

Adult PKU. Important Information for You. Mead Johnson Metabolics

PAH phenylalanine + oxidant tyrosine CH 2 +H 3 N

Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four

Urinary Aspartate Transaminase in Childhood

Clinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy. December Reference : NHSCB/E6/a

Not intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age

Phenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine

Purpose. Newborn Screening- UC 260. What is NBS? What isn t NBS? History. History 2

Estimation of Serum Urea. BCH472 [Practical] 1

Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria

CLINICAL REVIEWS. Phenylketonuria: J. S. Yu. M.B., M.R.A.C.P., D.C.H. Department of Child Health, University of Sydney,

RayBio Phenylalanine Fluorometric Assay Kit

Human inherited diseases

number Done by Corrected by Doctor

Conversion of amino acids الفريق الطبي األكاديمي

The spectrum and outcome of the. neonates with inborn errors of. metabolism at a tertiary care hospital

IT0STUDY PROTEIN METABOLISM with special reference to tyrosine as well as to study the deranged metabolism of aromatic compounds in

(From the Department of Pediatrics, Medical Faculty, Tohoku Imperial University, Sendai. Director: Prof. A. Sato)

PROTEIN METABOLISM: SPECIFIC WAYS OF AMINO ACIDS CATABOLISM AND SYNTHESIS

- Aya Alomoush. - Talal Al-Zabin. - Belal Azab. 1 P a g e

A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients

More recently, the method has been adapted for testing newborn infants before leaving. for assay. The discs are placed within numbered

So Much More Than The PKU Test

Student Number: To form the polar phase when adsorption chromatography was used.

Artificial liver in PKU. Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology

Manual. Transfer step. Figure 1. Workflow comparison of manual phenylalanine assay and automated GSP Neonatal Phenylalanine assay

Chapter 9. Biotransformation

Final text for addition to The International Pharmacopoeia (June 2010)

NEONATAL TSH Screening ELISA. Cat. No.: MSUD Screening Assay Screening assay for the detection of Maple Sirup Urine Disease in Newborns

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Relationship between socioeconomic status and quality of life of children with phenylketonuria

Selective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain.

Enzyme histochemistry of skeletal muscle

Analysis of Neurotransmitters. Simon Heales

2. 2,4 Dinitro phenyl hydrazine (DNPH): I mm in 1N HCl. 5. Working standard: 1 in 20 dilution of the stock standard.

PKU, KUVAN, and You PKU treatment and support for adults and young adults

OBSERVATIONS ON THE SUBSTRATE SPECIFICITY OF DOPA DECARBOXYLASE FROM OX ADRENAL MEDULLA, HUMAN PHAEOCHROMOCYTOMA AND HUMAN ARGENTAFFINOMA

PHENYLKETONURIA. Debbie Galo

Table of Contents Preface...1 What is PKU?...2 Where does PKU come from?...3 How is PKU Treated?...4 Controlling Blood Phe *...5 Phenyl-Free How

Kinetics of Phenylalanine Disappearance after Intravenous ~ oad in Phenylketonuria and Its Genetic Variants

Medicine, Cambridge, England, and Wuppertal, B.A.O.R.

TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group

HUMAN BIOLOGY (SPECIFICATION A) Unit 9 (Written Synoptic)

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

GENOTYPE-PHENOTYPE CORRELATIONS IN GALACTOSEMIA COMPLICATIONS COMPLICATIONS COMPLICATIONS LONG-TERM CHRONIC COMPLICATIONS WITH NO CLEAR CAUSE

Student Number: THE UNIVERSITY OF MANITOBA April 10, 2000, 9:00 AM - 12:00 PM Page 1 (of 4) Biochemistry II Lab Section Final Examination

The What, Why and How of Large Neutral Amino Acids

Paediatric Clinical Chemistry

Lecture 10 - Protein Turnover and Amino Acid Catabolism

Module : Clinical correlates of disorders of metabolism Block 3, Week 2

Metabolic Disorders. Chapter Thomson - Wadsworth

Bio 100 Guide 08.

Urea Cycle Defects. Dr Mick Henderson. Biochemical Genetics Leeds Teaching Hospitals Trust. MetBioNet IEM Introductory Training

Optical Rotatory Dispersion and Circular Dichroism of Amino Acid Hydantoins

Welcome to this four part series focused on epidemiologic and biostatistical methods related to disease screening. In this first segment, we will

BIOCHEMISTRY Protein Metabolism

Transcription:

Tohoku J. exp Med., 1969, 100, 249-253 Two Siblings of Hyperphenylalaninemia: Suggestion to a Genetic Variant of Phenylketonuria Keiya Tada, Toshio Yoshida, Keiko Mochizuki, Tasuke Konno, Hiroshi Nakagawa, Yoshimasa Yokoyama, Goro Takada and Tsuneo Arakawa Department of Pediatrics (Prof. Ts. Arakawa), Faculty of Medicine, Tohoku University, Sendai A sibling case of hyperphenylalaninemia without phenylpyruvic aciduria was described. An oral loading of phenylalanine revealed a delay of clearance of serum phenylalanine, a slight elevation of serum tyrosine, and an increased urinary excretion of phenylpyruvic acid and Ē-hydroxyphenylacetic acid. Phenylalanine hydroxylase in the liver was found to be of about one-tenth the normal activity. These findings suggest that hyperphenlyalaninemia may be a genetic variant of phenylketonuria. The screening program for phenylketonuria (PKU) which has been widely going on in the neonatal period revealed the existence of hyperphenylalaninemia. The latter is differentiated from classical PKU in that the elevation of blood phenylalanine is milder and the ferric-chloride test for urinary phenylpyruvic acid is negative. The biochemical mechanism through which this peculiar hyper phenylalaninemia is caused remains obscure, although several possibilities have been postulated.1 This paper describes the results of biochemical studies on two siblings of hyperphenylalaninemia. CASE REPORT Case N. S., a boy was born with a weight of 2,620g after a full-term pregnancy. Blue asphyxia was seen at birth. Neonatal period was uneventful. Since three months of age he began to show convulsions like infantile spasm. At the age of three years, the patient was admitted to our hospital because of frequent episodes of convulsions. He showed signs of spastic tetraplegia. IQ was found to be below 30. EEG showed findings of hypsarrhythmia. Analyses of free amino acids in serum showed an elevation of phenylalanine ranging from 6 to 12mg/100ml and other amino acids including tyrosine were within normal limits (cf. Table 1). Urinary ferric-chloride test was never positive. The parents were healthy but consanguineous (first cousins). There were two siblings, one being healthy and the other found to have hyperphenylalaninemia (Case K. S.). Received for publication, November 19, 1969. 249

250 K. Tada et al. TABLE 1. Serum amino acid levels in the patients with hyperphenylalaninemia (mg/100ml) Case K. S., a younger brother of Case N. S., was born after a full-term pregnancy and spontaneous delivery with a weight of 3,020g. His neonatal history was uneventful. At the age of 30 days, the patient had the first attack of convulsions like infantile spasm. At the age of 40 days, the patient was admitted to our hospital, and physical examination revealed a moderately nourished boy with eczema on the head and face. There was no neurologically abnormal signs. DQ was fond to be 79. EEG showed findings of hypsarrhythmia. Determination of serum amino acids showed an elevation of phenylalanine ranging from 12 to 15mg/100ml and normal range of the other amino acids. Urinary ferric chloride test was mostly negative, sometimes weakly positive. Since 45 days of life, the treatment with a low phenylalanine diet was started. During the treatment, levels of serum phenylalanine were maintained between 2 to 6mg/100ml. At the age of 20 months, the patient showed satisfactory development, DQ being of 83. The parents and a healthy sibling showed normal levels of serum phenylalanine (cf. Table 1). SPECIFIC STUDIES An oral phenylalanine loading test (0.1g/kg) in Case N. S. showed a higher peak of serum phenylalanine and its delay in returning to the pre-loading level, following the test dose (cf. Fig. 1). Urine specimens following the phenylalanine loading of Case N. S. and Case K. S. gave positive reaction for both the FeCl3 test and the dinitrophenylhydrazine test, indicating an increased excretion of phenylpyruvic acid. Ē-hydroxyphenyl acetic acid (Ē-hpaa) was investigated by Berry's paperchromatographic procedure2. A spot of Ē-hpaa was undetectable in urine from Case K. S. under the ordinary diet but it appeared in urine following the phenylalanine loading.

Two Siblings of Hyperphenylalaninemia 251 Fig. 1. Oral phenylalanine loading test (0.10g/kg). TABLE 2. Serum tyrosine levels following the phenylalanine loading (0.2g/kg) Serum tyrosine levels after the phenylalanine loading were determined in Case K. S. by an automatic amino acid analyzer (cf. Table 2). A slight rise in serum tyrosine after the loading was found in Case K. S., in contrast to no rise in a case of classical PKU. These results suggest a residual activity of phenylalanine hydroxylase in our case of hyperphenylalaninemia. In order to confirm this point, the activity of phenylalanine hydroxylase in the liver was determined by Justice et al.'s method3 as follows. Liver specimens obtained by the needle-biopsy from the patients were immediately homogenized

252 K. Tada et al. with three volumes of 0.15M potassium chloride. The homogenate was centrifuged at 16,000g for 15 minutes, and the supernatant was immediately used for assay of phenylalanine hydroxylase activity. The incubation mixture contained 0.8 ƒê mole L-phenylalanine (including 0.2ƒÊc of uniformly labeled 14C-phenylalanine), 1.0ƒÊmole NADH, 2ƒÊmole nicotinamide, 0.04ml of liver extract and 0.2M phosphate buffer, ph 7.0, with a final volume of 0.6ml. Incubation was carried out at 25 Ž for 45 minutes and stopped by the addition of 0.6ml of 10% trichloro acetic acid. The reaction mixture was centrifuged at 2,000g and an aliquot of the supernatant was applied to Toyoroshi No. 51. Ascending chromatography was carried out with a solvent system consisting of 2-propanol/water/ammonium hydroxide (8:1:1v/v) for 18 hours. The paper was scanned for radioactivity using a strip counter. Chromatograms were compared with authentic L-phenyl alanine and tyrosine standards for mobility and position. Results are shown in Fig. 2; the patient of classical PKU showed no peak of radioactivity in tyrosine fraction. Case K. S. showed a slight but significant peak in tyrosine fraction, corre spondent to about one-tenth to one-fifteenth that in controls. These results indicate that our patient with hyperphenylalaninemia has a partial defect in the activity of phenylalanine hydroxylase of the liver. Fig. 2. Activity of phenylalanine hydroxylase in the liver

Two Siblings of Hyperphenylalaninemia 253 COMMENT Hyperphenylalaninemia without phenylpyruvic aciduria could be caused by any of the following mechanisms; a defect in phenylalanine transaminase, hetero zygote of classical PKU, a delayed maturation of tyrosine oxidation system or a partial defect of phenylalanine hydroxylase.1 In our patients with hyperphenylalaninemia, a defect in phenylalanine transaminase can be excluded because these patients were found to excrete phenylpyruvic acid after the phenylalanine loading. The absence of urinary phenylpyruvic acid is, therefore, ascribed to relatively low phenylalanine levels in blood as compared with those in classical PKU. This explanation would be consistent with the observation that phenylpyruvic aciduria disappeared in the course of dietary treatment of PKU with the decrease of serum phenylalanine levels and that critical level of serum phenylalanine for positive FeCl3 test was thought to be about 15mg/100ml.4 The possibility of heterozygosity for PKU is also unlikely, because most hetero zygotes for PKU show normal levels of serum phenylalanine in the fasting state. Normal levels of serum tyrosine in our patients with hyperphenylalaninemia deny the possibility of delayed maturation of tyrosine oxidation system. A partial defect of phenylalanine hydroxylase was demonstrated in two cases of hyperphenylalaninemia by Justice et al.3 The present studies of ours on siblings of hyperphenylalaninemia not only suppport their findings, but also strongly suggest that hyperphenylalaninemia, at least persistent form, may be a genetic variant of PKU. Most of the patients with hyperphenylalaninemia reported so far have no mental retardation. Our siblings with hyperphenylalaninemia showed, however, mental retardation. There is a possibility that the patients with hyperphenyl alaninemia might be susceptible to brain damage. References 1) Auerbach, V. H., Digeorge, A. M. & Carpenter, G. G. Amino Acid Metabolism and Genetic Variation, edited by William L. Nyhan, McGraw-Hill Book Company, New York, 1967, p. 11. 2) Berry, H. K., Umbarger, B. & Sutherland, B. S. Procedures for monitoring the low phenylalanine diet in treatment of phenylketonuria. J. Pediat., 1965, 67, 609-616. 3) Justice, P., O'Flynn, M. E. & Hsia, D. Y. Y. Phenylalanine-hydroxylase activity in hyperphenylalaninemia. Lancet, 1967, 1, 928-929. 4) Armstrong, M. D. & Tyler, F. H. Studies on phenylketonuria. 1. Restricted phenylalanine intake in phenylketonuria. J. clin. Invest., 1955, 34, 565-580.